Please login to the form below

Not currently logged in
Email:
Password:

Sir John Bell

This page shows the latest Sir John Bell news and features for those working in and with pharma, biotech and healthcare.

‘Streamlined’ medicines regulation promised in ‘No Deal’ Brexit scenario

‘Streamlined’ medicines regulation promised in ‘No Deal’ Brexit scenario

Professor Sir John Bell, a leading UK academic scientist and lead author of the Life Sciences Sector Deal recently indicated he believed the MHRA, using its world-class expertise, could make

Latest news

  • AI company Sensyne raises £60m in IPO AI company Sensyne raises £60m in IPO

    It also has a high-profile board, including NHS England’s Sir Bruce Keogh and eminent immunologist and geneticist Professor Sir John Bell, who will serve as non-executive chairman.

  • Brexit rebels win vote on European Medicines Agency alignment Brexit rebels win vote on European Medicines Agency alignment

    Brexit rebels win vote on European Medicines Agency alignment. EMA membership will be a key negotiating aim; Sir John Bell sees independent MHRA post-Brexit. ... Sir John Bell, life sciences leader and author of the UK life sciences industrial strategy

  • UK trumpets life sciences post-Brexit ‘sector deal’ UK trumpets life sciences post-Brexit ‘sector deal’

    The sector deal follows the UK’s industrial strategy white paper – drawn up by geneticist Sir John Bell – which pledged a series of new R&D investments. ... As laid out in Sir John’s paper, the sector deal focuses on key themes including

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    s position for the good of the country, and that's what Sir John Bell clearly indicates.". ... In which case I think there's a fantastic future. If we fail to respond to it we're going to have some hard times and the Sir John Bell report

  • UK life sciences sector sets out its post-Brexit growth proposals UK life sciences sector sets out its post-Brexit growth proposals

    UK life sciences sector sets out its post-Brexit growth proposals. Review helmed by Sir John Bell outlines a wide-ranging strategy. ... It’s helmed by geneticist Sir John Bell, who was tasked by the government to bring industry together to set out the

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pulling together Pulling together

    Responding to these at the end of August saw Sir John Bell publish his ambitious Life Sciences Industrial Strategy report, which offers a wide-ranging plan for making the UK a ... It’s a theme that appears in Sir John Bell’s report, where one of its

  • Pharma deals in March 2015 Pharma deals in March 2015

    Sir John Bell, Regius Professor of Medicine at Oxford University and a non-executive director of Immunocore has criticised the City of London for failing to provide financial support to life

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Life at the end of the Brexit tunnel

    Sir John Bell outlined the Life Sciences Industrial Strategy, which includes £160 million of funding to support the health sector, including the NHS. ... As an example of this, Sir John Bell suggested that Artificial Intelligence could be combined with

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics